21 results on '"Feliu, J."'
Search Results
2. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas
- Author
-
Viñal, D., Martinez, D., Garcia-Cuesta, J. A., Gutierrez-Sainz, L., Martinez-Recio, S., Villamayor, J., Martinez-Marin, V., Gallego, A., Ortiz-Cruz, E., Mendiola, M., Pozo-Kreilinger, J. J., Berjon, A., Belinchon, B., Bernabeu, D., Espinosa, E., Feliu, J., and Redondo, A.
- Published
- 2020
- Full Text
- View/download PDF
3. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients
- Author
-
Feliu, J., Heredia-Soto, V., Gironés, R., Jiménez-Munarriz, B., Saldaña, J., Guillén-Ponce, C., and Molina-Garrido, M. J.
- Published
- 2020
- Full Text
- View/download PDF
4. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
- Author
-
Gómez-España, M. A., Gallego, J., González-Flores, E., Maurel, J., Páez, D., Sastre, J., Aparicio, J., Benavides, M., Feliu, J., and Vera, R.
- Published
- 2019
- Full Text
- View/download PDF
5. SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013
- Author
-
Casado-Saenz, E., Feliu, J., Gomez-España, M. A., Sanchez-Gastaldo, A., and Garcia-Carbonero, R.
- Published
- 2013
- Full Text
- View/download PDF
6. Prediction of Unplanned Hospitalizations in Older Patients Treated with Chemotherapy
- Author
-
Feliu J, Espinosa E, Basterretxea L, Paredero I, Llabrés E, Jiménez-Munárriz B, Losada B, Pinto A, Custodio AB, Muñoz MDM, Gómez-Mediavilla J, Torregrosa MD, Cruz P, Higuera O, and Molina-Garrido MJ
- Subjects
older patient ,geriatric assessment ,risk score ,chemotherapy ,unplanned hospitalizations - Abstract
Simple Summary Unplanned hospitalizations (UHs) are common among elderly patients with cancer who receive chemotherapy. This fact decreases quality of life or performance status and increases health costs. Our objective was to determine predictive factors for UH in this population. A score based on six variables taken from geriatric assessment and chemotherapy characteristics was developed in a series of 493 elderly patients receiving chemotherapy. The use of this score may reliably identify patients at risk for UH, thus helping to plan treatment, implement adaptive measures, and set up a close follow-up schedule. Purpose: To determine the incidence of unplanned hospitalization (UH) and to identify risk factors for UH in elderly patients with cancer who start chemotherapy. Methods: In all, 493 patients over 70 years starting new chemotherapy regimens were prospectively included. A pre-chemotherapy geriatric assessment was performed, and tumor and treatment variables were collected. The association between these factors and UH was examined by using multivariable logistic regression. Score points were assigned to each risk factor. Results: During the first 6 months of treatment, 37% of patients had at least one episode of UH. Risk factors were the use of combination chemotherapy at standard doses, a MAX2 index >= 1, a Charlson comorbidity score >= 2, albumin level = 1, and weight loss >5%. Three risk groups for UH were established according to the score in all patients: 0-1: 17.5%; 2: 34%; and 3-7: 57% (p < 0.001). The area under receiver operation characteristic (ROC) curve was 0.72 (95% CI: 0.67-0.77). Conclusion: This simple tool can help to reduce the incidence of UH in elderly patients with cancer who are scheduled to initiate chemotherapy treatment.
- Published
- 2021
7. Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study
- Author
-
Feliu J, Jiménez-Munárriz B, Basterretxea L, Paredero I, Llabrés E, Antonio-Rebollo M, Losada B, Espinosa E, Gironés R, Custodio AB, Muñoz MDM, Díaz-Almirón M, Gómez-Mediavilla J, Pinto A, Torregrosa MD, Soler G, Cruz P, Higuera O, and Molina-Garrido MJ
- Subjects
Toxicity risk score ,Older patient ,Toxicity ,Chemotherapy ,Geriatric assessment - Abstract
Background Standard oncology tools are inadequate to distinguish which older patients are at higher risk of developing chemotherapy-related complications. Materials and Methods Patients over 70 years of age starting new chemotherapy regimens were prospectively included in a multicenter study. A prechemotherapy assessment that included sociodemographics, tumor/treatment variables, and geriatric assessment variables was performed. Association between these factors and the development of grade 3-5 toxicity was examined by using logistic regression. Results A total of 551 patients were accrued. Chemotherapy doses (odds ratio [OR] 1.834; 95% confidence interval [CI] 1.237-2.719) and creatinine clearance (OR 0.989; 95% CI 0.981-0.997) were the only factors independently associated with toxicity. Only 19% of patients who received reduced doses of chemotherapy and had a creatinine clearance >= 40 mL/minute had grade 3-4 toxicity, compared with 38% of those who received standard doses or had a creatinine clearance
- Published
- 2020
8. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas
- Author
-
Feliu, J., Sáenz, J. García, Jaráiz, A. Rodríguez, Castañón, C., Cruz, M., Fonseca, E., Lomas, M., Castro, J., Jara, C., Casado, E., León, A., and Barón, M. González
- Published
- 2006
- Full Text
- View/download PDF
9. Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer
- Author
-
de Carpeño, Javier Castro, Barón, M. González, Aguiar, J., Chacón, J. I., Feliu, J., García, M. J., Madroñal, C., Colmenarejo, A., Sánchez, J. J., Ordóñez, A., and The Oncopaz Cooperative Group (Spain)
- Published
- 2006
- Full Text
- View/download PDF
10. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma
- Author
-
De Castro, J., Lorenzo, A., Morales, S., Belón, J., Dorta, J., Lizón, J., Madroñal, C., Gallurt, P. M., Casado, E., Feliu, J., Barón, M. González, and Oncopaz Cooperative Group
- Published
- 2005
- Full Text
- View/download PDF
11. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer
- Author
-
Feliu, J., Martín, G., Madroñal, C., Rodríguez-Jaráiz, A., Castro, J., Rodríguez, A, Checa, T., Bolaño, M., Casado, E., and González-Barón, M.
- Published
- 2003
- Full Text
- View/download PDF
12. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen
- Author
-
Feliu, J., Barón, M. Gonzáles, Chacón, J. I., Espinosa, E., Garrido, P., Castro, J., Escobar, Y., Colmenarejo, A., Jara, C., Girón, C. García, Espinosa, J., Ordóñez, A., and ONCOPAZ Cooperative Group
- Published
- 1996
- Full Text
- View/download PDF
13. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ cooperative group
- Author
-
González-Barón, M., Feliu, J., Espinosa, E., García-Girón, C., Chacón, I., Garrido, P., Colmenarejo, A., Ordóñez, A., and Zamora, P.
- Published
- 1995
- Full Text
- View/download PDF
14. Can we avoid the toxicity of chemotherapy in elderly cancer patients?
- Author
-
Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C, and Molina-Garrido MJ
- Subjects
Elderly ,Toxicity ,Chemotherapy ,Risk score ,Geriatric assessment ,Cancer - Abstract
Although approximately 50% of cancer patients are 70 years of age or older, cancer treatment in the elderly remains a therapeutic challenge. The elderly form a very heterogeneous group in relation to their general health state, degree of dependence, comorbidities, performance status, physical reserve and geriatric situation, for which therapeutic decisions must be made in an individualized manner. In addition, changes in pharmacokinetics and pharmacodynamics of the drugs occur with age, as well as the tolerance of the tissues, leading to a narrowing of the therapeutic margin and an increase in toxicity. In the general population, Performace Status (PS) has traditionally been used to estimate tolerance to chemotherapy, but in the elderly population it is not useful. In this review we summarize the current knowledge about the pharmacology of antineoplastic drugs in the elderly and the tools available to help us identify risk of chemotherapy toxicity in these patients.
- Published
- 2018
15. Treatment options for colorectal cancer in the elderly.
- Author
-
Feliu, J., Castro, J., Belda, C., Sundlov, A., Casado, E., and González-Barón, M.
- Subjects
COLON cancer ,CANCER treatment ,THERAPEUTICS ,MEDICAL care for older people ,GERIATRICS - Abstract
The median age at diagnosis of colorectal cancer is during the seventh decade of life, and the incidence of the disease increases continuously with age. However, as the age of the patient increases, the possibilities of receiving adequate cancer treatment diminishes and the mortality rises. Thus, there is a huge need to redefine treatment strategies in elderly patients with colorectal carcinoma. The geriatric population is a very heterogeneous group where patients with an excellent health status coexist with those with both comorbidities and functional dependency. Therefore, it is necessary to personalize treatment in relation to the degree of vulnerability of the elderly patient. It is essential to perform a multidimensional geriatric assessment in order to consider the cancer and the stage, as well as to identify features that could modify survival or interfere with therapy. The aim of this review is to discuss the factors that are relevant for therapeutic management in elderly patients. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
16. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.
- Author
-
Feliu, J., Salud, A., Escudero, P., López-Gómez, L., Pericay, C., Castañón, C., López de Tejada, M. R., Rodríguez-García, J. M., Martínez, M. P., Martín, M. Sanz, Sánchez, J. J., Barón, M. González, López-Gómez, L, Castañón, C, de Tejada, M R López, Rodríguez-García, J M, Martínez, M P, Martín, M Sanz, Sánchez, J J, and Barón, M González
- Subjects
- *
COLON cancer , *DRUG therapy , *NEUTROPENIA , *CANCER treatment , *AMINOTRANSFERASES , *ANEMIA - Abstract
To evaluate the efficacy and toxicity of irinotecan (CPT-11) in combination with raltitrexed as first-line treatment of advanced colorectal cancer (CRC). A total of 91 previously untreated patients with advanced CRC and measurable disease were enrolled in this phase II study. The median age was 62 years (range 31-77); male/female 54/37; ECOG performance status was 0 in 50 patients (55%), one in 39 (43%) and two in two (2%). Treatment consisted of CPT-11 350 mg x m(-2) in a 30-min intravenous infusion on day 1, followed after 30 min by a 15-min infusion of raltitrexed 3 mg x m(-2). Measurements of efficacy included the following: response rate, time to disease progression and overall survival. Of the 83 evaluable patients valuable to objective response, there were five complete responses (6%) and 23 partial responses (28%), for an overall response rate of 34% (95% CI: 25.9-46.5%). In all, 36 patients (43%) had stable disease, whereas 19 (23%) had a progression. The median time to progression was 11.1 months and the median overall survival was 15.6 months. A total of 487 cycles of chemotherapy were delivered with a median of five per patient. Grade 3-4 WHO toxicities were as follows: diarrhoea in 13 patients (15%), nausea/vomiting in four (4%), transaminase increase in six (7%), stomatitis in two (2%), febrile neutropenia in three (3%), anaemia in five (6%) and asthenia in three (3%). The combination CPT-11-raltitrexed is an effective, well-tolerated and convenient regimen as front-line treatment of advanced CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
17. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen
- Author
-
Feliu, J., Mel, J.R., Camps, C., Escudero, P., Aparicio, J., Menéndez, D., Garcıa Girón, C., Rodriguez, M.R., Sánchez, J.J., and González Barón, M.
- Subjects
- *
COLON cancer , *DRUG therapy - Abstract
In spite of the high prevalence of advanced colorectal cancer in the elderly, we have little data on the efficacy and toxicity of chemotherapy in this age group. Raltitrexed is a thymidylate synthetase inhibitor with known activity in the treatment of advanced colorectal cancer. The objective of this study was to analyse the efficacy and tolerance of raltitrexed in elderly patients with advanced colorectal cancer. 92 patients diagnosed with advanced colorectal cancer aged ⩾70 years were entered into the study. Raltitrexed was given at a dose of 3 mg/m2 once every 3 weeks for a minimum of three cycles. A total of 511 cycles were given with a median of five cycles per patient. 20 out of the 90 patients evaluable for response achieved a partial response (PR) (22%, 95% Confidence Interval (CI): 17–36%), 43 (48%) remained stable and 27 showed progression (30%). The mean duration of response was 24 weeks and the progression-free interval was 15 weeks. The overall median survival was 41 weeks. 31 patients (39%, 95% CI: 28–50%) experienced a clinical benefit (improvement of the performance status without a worsening of symptoms or relief of symptoms without a worsening of the performance status). The main toxicities were gastrointestinal and haematological. 12 patients (13%) developed grade 3-4 side-effects: 7 had nausea/vomiting (8%), 6 a transaminase increase (7%), 4 asthenia (4%), 3 diarrhoea (3%), 2 neutropenia (2%), 2 anaemia (2%) and 1 thrombocytopenia (1%). Three toxic deaths occurred (3%). The group of patients with a creatinine clearance ⩽1.08 ml/s was found to have a higher risk of developing grade 3-4 toxicity compared with those with adequate renal function (8/18 versus 4/72; P<0.001). In conclusion, raltitrexed is an active, convenient and low toxicity treatment for the elderly with advanced colorectal cancer. However, it must be used cautiously in elderly patients with a creatinine clearance ⩽1.08 ml/s since they are at a higher risk of suffering grade 3-4 toxicity. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
18. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)
- Author
-
E. Dotor, Esther González, Jaime Feliu, Ruth Vera, Berta Laquente, E. Martínez, Jose Luis Manzano, Teresa Macarulla, Joan Maurel, M. Salgado, [Vera, R.] Complejo Hosp Navarra, Dept Med Oncol, C Irunlarrea 3, Pamplona 31008, Spain, [Dotor, E.] Consorcio Sanitario Terrassa, Barcelona, Spain, [Feliu, J.] Hosp Univ La Paz, Madrid, Spain, [Gonzalez, E.] Complejo Hosp Univ Granada Virgen de las Nieves, Granada, Spain, [Laquente, B.] Hosp Duran & Reynals, ICO Hospitalet LLobregat, Lhospitalet De Llobregat, Spain, [Macarulla, T.] Hosp Valle De Hebron, Barcelona, Spain, [Martinez, E.] Hosp Univ Marques Valdecilla, Santander, Spain, [Maurel, J.] Hosp Clinic & Prov Barcelona, Barcelona, Spain, [Salgado, M.] Complexo Hosp Orense CHUO, Orense, Spain, [Manzano, J. L.] Hosp Badalona Germans Trias & Pujol, ICO Badalona, Barcelona, Spain, and [Vera,R] Department of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain. [Dotor,E] Consorcio Sanitario de Terrassa, Barcelona, Spain. [Feliu,J] Hospital Universitario la Paz, Madrid, Spain. [González,E] Complejo Hospitalario Universitario de Granada Virgen de las Nieves, Granada, Spain. [Laquente,B] ICO-Hospitalet de LLobregat, Hospital Duran i Reynals, Hospitalet de Llobregat, Spain. [Macarulla,T] Hospital Vall`Hebron, Barcelona, Spain. [Martínez,E] Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Maurel,J] Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Salgado,M] Complexo Hospitalario de Orense (CHUO), Ourense, Spain. [Manzano,JL] ICO-Badalona, Hospital Germans Trias i Pujol, Barcelona, Spain.
- Subjects
Oncology ,Cancer Research ,Survival ,FOLFIRINOX ,medicine.medical_treatment ,España ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Risk Factors ,030212 general & internal medicine ,American society ,Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] ,Follow-up ,Folinic acid ,General Medicine ,Humanos ,Treatment Outcome ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Folfirinox ,Fluorouracil ,Factores de riesgo ,medicine.drug ,medicine.medical_specialty ,Clinical Guides in Oncology ,Adenocarcinoma ,Guidelines ,Health Care::Health Services Administration::Quality of Health Care::Quality Assurance, Health Care::Guidelines as Topic::Practice Guidelines as Topic [Medical Subject Headings] ,03 medical and health sciences ,Internal medicine ,Pancreatic cancer ,medicine ,Humans ,Diagnostic ,Radical surgery ,Survival rate ,Chemotherapy ,business.industry ,Neoplasias pancreáticas ,Cancer ,Guideline ,Resection ,medicine.disease ,Gemcitabine ,Adjuvant chemotherapy ,Surgery ,Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [Medical Subject Headings] ,Treatment ,Pancreatic Neoplasms ,Spain ,business ,Guías de práctica clínica como asunto - Abstract
Journal Article; Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future. Yes
- Published
- 2016
19. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
- Author
-
Marta Martin-Richard, Joan Maurel, Jaime Feliu, Teresa Fernandez, Maria Elena Sanchez, Isabel Sevilla, Jaume Capdevila, Ana Leon, Rocio Garcia-Carbonero, Miriam López-Gómez, Ismael Ghanem, Vicente Alonso-Orduña, Laura Cerezo, Carmen Castanon, Pilar García-Alfonso, Monica Caro, Inmaculada Guasch, Begona Quintana-Angel, Carles Conill, Carlos F. Lopez, Amgen, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ), Institut Català de la Salut, [Feliu J] Department of Medical Oncology, CIBERONC, Catedra UAM-AMGEN, Hospital Universitario La Paz, Madrid, Spain. [Garcia-Carbonero R] Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain. Department of Medical Oncology, imas12, UCM, CNIO, CIBERONC, Hospital Universitario 12 de Octubre, Madrid, Spain. [Capdevila J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Guasch I] Department of Medical Oncology, Hospital Althaia-Manresa, Manresa, Spain. [Alonso-Orduna V] Department of Medical Oncology, Instituto de Investigacion Sanitaria de Aragon, Hospital Universitario Miguel Servet, Zaragoza, Spain. [Lopez C] Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Colorectal cancer ,medicine.medical_treatment ,Phases of clinical research ,chemotherapy ,Severity of Illness Index ,Gastroenterology ,Target therapy ,Recte - Càncer - Quimioteràpia ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales::neoplasias del recto::neoplasias del ano [ENFERMEDADES] ,neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma de células escamosas [ENFERMEDADES] ,Rectal cancer ,Original Research ,Aged, 80 and over ,Proctectomy ,Panitumumab ,Middle Aged ,Anal canal ,Anus Neoplasms ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Recte - Càncer - Radioteràpia ,Primary tumor ,Neoadjuvant Therapy ,Survival Rate ,medicine.anatomical_structure ,Oncology ,terapéutica::tratamiento combinado::quimiorradioterapia::quimiorradioterapia complementaria [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,030220 oncology & carcinogenesis ,Female ,Fluorouracil ,Radiodermatitis ,medicine.drug ,Adult ,medicine.medical_specialty ,Neutropenia ,Medicina ,Mitomycin ,lcsh:RC254-282 ,Disease-Free Survival ,03 medical and health sciences ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Rectal Neoplasms::Anus Neoplasms [DISEASES] ,Internal medicine ,medicine ,Humans ,Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Squamous Cell [DISEASES] ,Chemotherapy ,Radiology, Nuclear Medicine and imaging ,rectal cancer ,radiotherapy ,Aged ,Radiotherapy ,target therapy ,business.industry ,Therapeutics::Combined Modality Therapy::Chemoradiotherapy::Chemoradiotherapy, Adjuvant [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Clinical Cancer Research ,Chemoradiotherapy, Adjuvant ,medicine.disease ,Radiation therapy ,Regimen ,030104 developmental biology ,business ,Follow-Up Studies - Abstract
Aim VITAL, a phase II single‐arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5‐fluorouracil (5‐FU), mitomycin‐C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal canal (SCCAC). Methods Adult, treatment‐naïve SCCAC patients (Stage T2‐T4, any N, M0) and ECOG‐PS ≤2, received panitumumab (6 mg/kg, day 1 and Q2W; 8 weeks), 5‐FU (1000 mg/m2/d, days 1‐4 and 29‐32), MMC (10 mg/m2, days 1 and 29) and RT 45 Gy (1.8 Gy/fraction) to the primary tumor and mesorectal, iliac and inguinal lymph nodes, plus 10‐15 Gy boost dose to the primary tumor and affected lymph nodes. The primary objective was disease free survival rate (DFS) at 3‐years (expected 3‐year DFS rate: 73.7 ± 12%). Results Fifty‐eight patients (31 women; median age: 59 years; ECOG‐PS 0‐1:98%; TNM II [29%] (T2 or T3/N0/M0)/IIIA (T1‐T3/N1/M0 or T4/N0/M0) [21%]/IIIB (T4/N1/M0 or any T/N2 or N3/M0) [47%]/nonevaluable [4%]) were included. The median follow‐up was 45 months. The 3‐year DFS rate was 61.1% (95% CI: 47.1, 72.4). The 3‐year overall survival rate was 78.4% (95% CI: 65.1, 87.1). Eighteen patients (31.0%) required a colostomy within 2 years posttreatment. Grade 3‐4 toxicities were experienced by 53 (91%) patients. Most common grade 3‐4 treatment‐related events were radiation skin injury (40%) and neutropenia (24%). No toxic deaths occurred. Improved efficacy in colostomy‐free survival and complete response rate was observed in human papilloma virus positive patients. Conclusions Panitumumab addition to MMC‐5FU regimen in SCCAC patients increases toxicity and does not improve patients’ outcomes. RT plus MMC‐5FU remains the standard of care for localized SCCAC patients., VITAL, a phase II single‐arm study, was aimed to evaluate efficacy and safety of panitumumab addition to 5‐fluorouracil (5‐FU), mitomycin‐C (MMC) and radiotherapy in patients with localized squamous cell carcinoma of the anal canal (SCCAC). The study concluded that panitumumab addition to MMC‐5FU regimen in SCCAC patients increases toxicity and does not improve patients’ outcomes.
- Published
- 2020
20. New insights in β-tubulin sequence analysis in non-small cell lung cancer
- Author
-
de Castro, J., Belda-Iniesta, C., Cejas, P., Casado, E., Fresno Vara, J.A., Hardisson, D., Sánchez, J.J., Feliu, J., Ordóñez, A., Nistal, M., and González-Barón, M.
- Subjects
- *
GENETIC mutation , *PACLITAXEL - Abstract
Scarce data are available regarding the molecular mechanisms implicated in paclitaxel resistance. There is controversial data about β-tubulin mutations role in paclitaxel resistance. We have conducted this trial to address the influence of β-tubulin mutations in paclitaxel resistance in advanced non-small cell lung cancer (NSCLC). A group of 15 patients were biopsied and diagnosed of stages IIIB and IV NSCLC. Tumor specimens were used for DNA isolation and exon 4 of HM40 β-tubulin isotype was amplified and automatically sequenced, using both intronic and exonic primers. Next, the chemotherapy schedule consisted of weekly paclitaxel (100 or 150 mg/m2×6) followed 2 weeks later by cisplatin 100 mg/m2 on day 1, gemcitabine 1000 mg/m2 on days 1 and 14, and vinorelbine 25 mg/m2 on days 1 and 14, every 28 days. Using exonic primers, gene sequence alterations were found in 13/15 (87%) patients, including transitions (codons 180 and 182) and one silent transversion (codon 195). Also, three transversions (codons 231, 234, and 235) were found in all patients and controls. All alterations disappeared when sequenced with intronic primers. Our results suggest that point mutations demonstrated with exonic primers but not with intronic ones are probably due to β-tubulin pseudogenes present in advanced NSCLC specimens. Even so, when these β-tubulin pseudogenes are found there is a clear relation with clinical response. Although these changes could be relevant in paclitaxel resistance, this observation must be proven in future clinical trials to resolve “the tubulin dilemma”. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
21. Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer
- Author
-
M. Biglietto, Jaime Feliu, Claudia Cardone, Rocio Garcia-Carbonero, Andrés Cervantes, Roberto Bordonaro, F Andreozzi, Erika Martinelli, Giacomo Bregni, Teresa Troiani, Vincenzo Sforza, Fortunato Ciardiello, Antonio Avallone, Filomena Calabrese, Antonio Febbraro, Stefano Cordio, Vincenzo Montesarchio, Anna Nappi, UAM. Departamento de Medicina, Cardone, C., Martinelli, E., Troiani, T., Sforza, V., Avallone, A., Nappi, A., Montesarchio, V., Andreozzi, F., Biglietto, M., Calabrese, F., Bordonaro, R., Cordio, S., Bregni, G., Febbraro, A., Garcia-Carbonero, R., Feliu, J., Cervantes, A., and Ciardiello, F.
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,Medicina ,medicine.medical_treatment ,colorectal cancer ,Placebo ,academic research ,lcsh:RC254-282 ,chemistry.chemical_compound ,Maintenance therapy ,Internal medicine ,Regorafenib ,medicine ,Clinical endpoint ,Original Research ,Chemotherapy ,maintenance treatment ,treatment ,business.industry ,funding ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,First line treatment ,chemistry ,Toxicity ,regorafenib ,business ,RAS WT - Abstract
Background In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), the role of maintenance therapy after first-line treatment with chemotherapy plus antiepidermal growth factor receptor (EGFR) monoclonal antibodies (MoAb) is still an object of debate. Methods We assessed the efficacy and safety of regorafenib as a switch maintenance strategy after upfront 5-fluorouracil-based chemotherapy plus an anti- EGFR MoAb in patients with RAS WT mCRC. RAVELLO was a phase III, international, double-blind, placebocontrolled, academic trial. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival and toxicity. Regorafenib or placebo were administered daily for 3 weeks of 4-week cycle until disease progression or unacceptable toxicity, up to 24 months. Results The study was stopped prematurely due to slow accrual and lack of funding after the randomisation of 21 patients: 11 in the regorafenib arm and 10 in the placebo arm. The small sample size precludes any statistical analysis. Toxicity was acceptable and consistent with the known regorafenib safety profile. Median PFS was similar in the two arms. However, a subgroup of patients treated with regorafenib experienced a remarkably long PFS. Three patients were progression free at 9 months in the regorafenib arm versus one patient in the placebo arm, whereas at 12 months two regorafenib-treated patients were still progression free versus none in the placebo arm. Conclusion RAVELLO trial demonstrated that growing financial and bureaucratic hurdles affect the feasibility of independent academic research. Although stopped prematurely and within the limited sample size, RAVELLO suggests that regorafenib has not a major activity in maintenance setting after upfront chemotherapy and anti-EGFR MoAb. However, a subgroup of patients experienced a remarkable long PFS, indicating that a better refinement of the patient population would help to identify subjects that might benefit from a regorafenib personalised approach in the switch maintenance setting
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.